Publications:

POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.

Clinical And Translational Medicine

Chen, Yan-Xing YX; Wang, Zi-Xian ZX; Yuan, Shu-Qiang SQ; Jiang, Teng-Jia TJ; Huang, You-Sheng YS; Xu, Rui-Hua RH; Wang, Feng F; Zhao, Qi Q

Publication Date: 2021-09

Variant appearance in text: POLE: K429N

PubMed Link: 34586735

Variant Present in the following documents:

• CTM2-11-e524-s001.xlsx, sheet 2
• CTM2-11-e524-s001.xlsx, sheet 6

View BVdb publication page

POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma.

Oncotargets And Therapy

Li, Yiran Y; He, Qizhi Q; Li, Shuangdi S; Wen, Xiaoli X; Ye, Lei L; Wang, Kai K; Wan, Xiaoping X

Publication Date: 2020

Variant appearance in text: POLE: K429N

PubMed Link: 32801757

Variant Present in the following documents:

• Main text
• ott-13-7305.pdf

View BVdb publication page

Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates.

Journal For Immunotherapy Of Cancer

Wang, Yu Y; Johnson, Douglas B DB; Lu, Steve S; Diaz, Luis A LA; Xu, Yaomin Y; Balko, Justin M JM

Publication Date: 2019-05-07

Variant appearance in text: POLE: K429N

PubMed Link: 31064401

Variant Present in the following documents:

• 40425_2019_584_MOESM3_ESM.xls, sheet 4

View BVdb publication page